Related Experiment Video
Updated: Sep 20, 2025

06:07
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
Published on: February 5, 2020
5.8K
Impact of PD-1 Blockade in Nonresponders: Pitfalls and Promise
Harry H Yoon1, Haidong Dong2, Qian Shi3
1Department of Oncology, Mayo Clinic, Rochester, Minnesota.
Abstract:
Exploratory analysis of a phase III trial in esophageal cancer found that the patients who most contributed to an overall survival benefit from PD-1 blockade were not responders, but non-responders. The analysis has limitations but may have implications for investigating the optimal timing of immunotherapy relative to other treatments. See related article by Okada et al., p. 3277.

